Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response
Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting
08:00am, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Fate Therapeutics Announces Participation in Upcoming Investor Conferences
04:01pm, Thursday, 12'th Nov 2020
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
04:13pm, Friday, 06'th Nov 2020
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
04:01pm, Thursday, 05'th Nov 2020
First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma
CAR-T Pipeline Insights Report 2020: Comprehensive Insights on 250+ Companies and Pipeline Drugs - ResearchAndMarkets.com
12:00am, Wednesday, 23'rd Sep 2020
The
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
12:00pm, Wednesday, 19'th Aug 2020
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies fo
What Kind Of Shareholders Own Fate Therapeutics, Inc. (NASDAQ:FATE)?
12:19pm, Tuesday, 11'th Aug 2020
Every investor in Fate Therapeutics, Inc. (NASDAQ:FATE) should be aware of the most powerful shareholder groups. Large...
How Much Of Fate Therapeutics, Inc. (NASDAQ:FATE) Do Institutions Own?
12:00pm, Tuesday, 11'th Aug 2020
The big shareholder groups in Fate Therapeutics, Inc. (NASDAQ:FATE) have power over the company. Large companies...
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
09:55pm, Wednesday, 05'th Aug 2020
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
08:01pm, Wednesday, 05'th Aug 2020
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT5
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
12:00am, Wednesday, 05'th Aug 2020
Stocks Analysis by Zacks Investment Research covering: S&P 500, Fate Therapeutics Inc. Read Zacks Investment Research's latest article on Investing.com
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
08:01pm, Tuesday, 04'th Aug 2020
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Sumitomo Mitsui Trust Holdings Inc. Has $18.26 Million Position in Fate Therapeutics Inc (NASDAQ:FATE)
06:42am, Tuesday, 04'th Aug 2020
Sumitomo Mitsui Trust Holdings Inc. lessened its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 42.5% during the second quarter, according to its most recent filing with the Securities & Ex
